Ask AI
ProCE Banner Activity

Augmentation Treatments for Major Depressive Disorder

Clinical Thought

Incomplete response to antidepressant treatment and persistent residual symptoms remain challenges in managing major depressive disorder. This ClinicalThought explores strategies for optimizing, switching, or augmenting antidepressant therapy, including approved second-generation antipsychotics, emerging pharmacologic options, and interventional treatments. Learn how symptom profiles, treatment response, and tolerability can guide individualized treatment decisions.

Released: November 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.

Target Audience

This activity is intended for healthcare professionals caring for patients with major depressive disorder, including physicians (psychiatrists and family medicine/primary care), nurse practitioners, physician associates, registered nurses, pharmacists, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess optimal timing and clinical rationale for switching or augmenting treatment in patients with MDD

  • Evaluate the pharmacologic profiles, efficacy, and safety of approved adjunctive therapies for adults with MDD that improve residual symptoms, including anhedonia and cognitive impairment

  • Apply current guideline- and evidence-based strategies to optimize dosing and titration of adjunctive therapies for adults with MDD who exhibit residual symptoms

  • Implement strategies for optimizing the management of persistent symptoms for complex or special populations with MDD to optimize long-term outcomes and functional recovery

Financial Disclosures

Primary Author

Joseph F. Goldberg, MD: consultant/advisor/speaker: AbbVie, Alkermes, Almatica, Alvogen, Axsome, Bristol Myers Squibb, Compass Pathways, Neurelis, Neurocrine, Neuroma, Otsuka, Puretech, Seaport, Vanda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.